Research Report

Gene–gene and gene–environment interactions in interferon therapy for chronic hepatitis C

Eugene Lin

† Author for correspondence

Vita Genomics, Inc, 7 Fl, No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan.

Search for more papers by this author

Email the corresponding author at eugene.lin@vitagenomics.com

Yuchi Hwang

Vita Genomics, Inc, 7 Fl, No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan.

Search for more papers by this author

Email the corresponding author at eugene.lin@vitagenomics.com

Ellson Y Chen

Vita Genomics, Inc, 7 Fl, No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan.

Search for more papers by this author

Email the corresponding author at eugene.lin@vitagenomics.com

Published Online:2 Nov 2007https://doi.org/10.2217/14622416.8.10.1327

View article

Abstract

Introduction: In studies of pharmacogenomics, it is essential to address gene–gene and gene–environment interactions to describe complex traits involving pharmacokinetic and pharmacodynamic mechanisms. In this work, our goal is to detect gene–gene and gene–environment interactions resulting from an analysis of chronic hepatitis C patients’ clinical factors including SNPs, viral genotype, viral load, age and gender. Materials & Methods: We collected blood samples from 523 chronic hepatitis C patients who had received interferon and ribavirin combination therapy. Based on the treatment strategy for chronic hepatitis C patients, we focused our search for candidate genes involved in pathways related to interferon signaling and immunomodulation. To investigate gene–gene and gene–environment interactions, we implemented an artificial neural network-based method for identifying significant interactions between clinical factors with the fivefold crossvalidation method and permutation tests. The artificial neural network model was trained by an algorithm with an adaptive momentum and learning rate. Results: A total of 20 SNPs were selected from six candidate genes including adenosine deaminase-RNA-specific (ADAR), caspase 5 (CASP5), interferon consensus sequence binding protein 1 (ICSBP1), interferon-induced protein 44 (IFI44), phosphoinositide-3-kinase catalytic γ polypeptide (PIK3CG), and transporter 2 ATP-binding cassette subfamily B (TAP2) genes. By applying our artificial neural network-based approach, IFI44 was found in the significant two-locus, three-locus and four-locus gene–gene effect models, as well as in the significant two-factor and three-factor gene–environment effect models. Furthermore, viral genotype remained in the best two-factor, three-factor and four-factor gene–environment models. These results support the hypothesis that IFI44 and viral genotype may play a role in the pharmacogenomics of interferon treatment. In addition, our approach identified a panel of ten clinical factors that may be more significant than the others for further study. Conclusion: We demonstrated that our artificial neural network-based approach is a promising method to assess the gene–gene and gene–environment interactions for interferon and ribavirin combination treatment in chronic hepatitis C patients by using clinical factors such as SNPs, viral genotype, viral load, age and gender.

Keywords:

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

1 Alberti A, Benvegnu L: Management of hepatitis C. J. Hepatol.38,S104–S118 (2003).Crossref, Medline, Google Scholar
2 Fried MW, Peter J, Hoots K et al.: Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon α-2b and ribavirin. Hepatology36,967–972 (2002).Crossref, Medline, CAS, Google Scholar
3 Hu KQ, Vierling JM, Redeker AG: Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J. Viral Hepat.8(1),1–18 (2001).Crossref, Medline, CAS, Google Scholar
4 Lai MY, Kao JH, Yang PM et al.: Long-term efficacy of ribavirin plus interferon α in the treatment of chronic hepatitis C. Gastroenterology111,1307–1312 (1996).Crossref, Medline, CAS, Google Scholar
5 Lauer GM, Walker BD: Hepatitis C virus infection. N. Engl. J. Med.345,41–52 (2001).Crossref, Medline, CAS, Google Scholar
6 Manns MP, McHutchison JG, Gordon SC et al.: Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet358,958–965 (2001).Crossref, Medline, CAS, Google Scholar
7 Fried MW, Shiffman ML, Reddy KR et al.: Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med.347,975–982 (2002).Crossref, Medline, CAS, Google Scholar
8 Ferenci P: Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J. Antimicrob. Chemother.53,15–18 (2004).Crossref, Medline, CAS, Google Scholar
9 Collier J, Chapman R: Combination therapy with interferon-α and ribavirin for hepatitis C: practical treatment issues. BioDrugs15(4),225–238 (2001).Crossref, Medline, CAS, Google Scholar
10 Martinot-Peignoux M, Marcellin P, Pouteau MP et al.: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon α therapy in chronic hepatitis C. Hepatology22,1050–1056 (1995).Crossref, Medline, CAS, Google Scholar
11 Fried MW, Hoofnagle JH: Therapy of hepatitis C. Semin. Liver Dis.15,82–91 (1995).Google Scholar
12 Yee LJ, Tang J, Gibson AW, Kimberly R, van Leeuwen DJ, Kaslow RA: Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology33(3),708–712 (2001).Crossref, Medline, CAS, Google Scholar
13 Hijikata M, Ohta Y, Mishiro S: Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt-88) correlated with the response of hepatitis C patients to interferon. Intervirology43(2),124–127 (2000).Crossref, Medline, CAS, Google Scholar
14 Sugimoto Y, Kuzushita N, Takehara T et al.: A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J. Viral Hepat.9(5),377–384 (2002).Crossref, Medline, CAS, Google Scholar
15 Hwang Y, Chen EY, Gu ZJ et al.: Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics7(5),697–709 (2006).•• Describes a multiple logistic regression method for assessing interferon responsiveness based on SNPs.Link, CAS, Google Scholar
16 Lin E, Hwang Y, Wang SC, Gu ZJ, Chen EY: An artificial neural network approach to the drug efficacy of interferon treatments. Pharmacogenomics7(7),1017–1024 (2006).•• Demonstrates an artificial neural network model for predicting interferon responses by clinical factors such as SNPs.Link, CAS, Google Scholar
17 Bell JT, Wallace C, Dobson R et al.: Two-dimensional genome-scan identifies novel epistatic loci for essential hypertension. Hum. Mol. Genet.15,1365–1374 (2006).Crossref, Medline, CAS, Google Scholar
18 Carlborg O, Haley CS: Epistasis: too often neglected in complex trait studies. Nature5,618–625 (2004).Google Scholar
19 Lin E, Hwang Y, Liang KH, Chen EY: pattern-recognition techniques with haplotype analysis in pharmacogenomics. Pharmacogenomics8(1),75–83 (2007).•• Reviews pattern recognition techniques for detecting gene–gene and gene–environment interactions.Link, CAS, Google Scholar
20 Kessler HH, Santner B, Umlauft F et al.: Detection of hepatitis C viral sequences in serum by 'nested’ polymerase chain reaction (PCR) and a commercial single-round PCR assay. Clin. Diagn. Virol.4,239–250 (1995).Crossref, Medline, CAS, Google Scholar
21 Pawlotsky JM: Use and interpretation of virological tests for hepatitis C. Hepatology36,S65–S73 (2002)Crossref, Medline, Google Scholar
22 Simmonds P: Variability of hepatitis C virus. Hepatology21,570–583 (1995)Crossref, Medline, CAS, Google Scholar
23 Lin E, Hwang Y, Tzeng CM: A case study of the utility of the HapMap database for pharmacogenomic haplotype analysis in the Taiwanese population. Mol. Diagn. Ther.10(6),367–370 (2006).Crossref, Medline, CAS, Google Scholar
24 Kung SY, Hwang JN: Neural networks for intelligent multimedia processing. Proc. IEEE86,1244–1272 (1998).Crossref, Google Scholar
25 Rumelhart DE, Hinton GE, William RJ: Learning internal representation by error propagation. In: Parallel Distributed Processing: Explorations in the Micro-Structure of Cognition, vol.1, Foundations. MIT Press, MA, USA (1996).Google Scholar
26 Neural Network Toolbox for use with MATLAB. The Mathworks Inc., Natick MA 01760–1500, USA (1998).Google Scholar
27 Nestorov I, Hadjitodorov ST, Petrov I, Rowland M: Empirical versus mechanistic modelling: comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetic relationships of a homologous series of barbiturates. AAPS PharmSci.1(4),17 (1999).Crossref, Google Scholar
28 Hastie T, Tibshirani R, Friedman JH: The Elements of Statistical Learning. Springer-Verlag, NY, USA (2001).Google Scholar
29 Bishop CM: Neural Networks for Pattern Recognition. Clarendon Press, NY, USA (1995).Google Scholar
30 Hirschhorn JN, Daly MI: Genome-wide association studies for common diseases and complex traits. Nature Review Genet.6,95–108 (2005).• Reviews the rationale and possible approaches for genetic association studies.Crossref, Medline, CAS, Google Scholar
31 North BV, Curtis D, Cassell PG, Hitman GA, Sham PC: Assessing optimal neural network architecture for identifying disease-associated multi-marker genotypes using a permutation test, and application to calpain 10 polymorphisms associated with diabetes. Nat. Rev. Genet.67348–6356 (2003).Google Scholar
32 Jensen DM, Morgan TR, Marcellin P et al.: Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology43(5),954–960 (2006).Crossref, Medline, CAS, Google Scholar
33 van Soest H, Boland GJ, van Erpecum KJ. Hepatitis C: changing genotype distribution with important implications for patient management. Neth. J. Med.64(4),96–99 (2006).Medline, CAS, Google Scholar
34 Maiellaro PA, Cozzolongo R, Marino P: Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C. Curr. Pharm. Des.10(17),2101–2109 (2004).Crossref, Medline, CAS, Google Scholar
35 Ma DQ, Whitehead PL, Menold MM et al.: Identification of significant association and gene–gene interaction of GABA receptor subunit genes in autism. Am. J. Hum. Genet.77(3),377–388 (2005).Google Scholar
36 Ritchie MD, Motsinger AA: Multifactor dimensionality reduction for detecting gene–gene and gene–environment interactions in pharmacogenomics studies. Pharmacogenomics6(8),823–834 (2005).Link, CAS, Google Scholar
37 Erb RJ: Introduction to backpropagation neural network computation. Pharm Res.10,165–170 (1993).Crossref, Medline, CAS, Google Scholar
38 Kitamura A, Takahashi K, Okajima A, Kitamura N: Induction of the human gene for p44, a hepatitis C-associated microtubular aggregate protein, by interferon-α/β. Eur. J. Biochem.224,877–883 (1994).Crossref, Medline, CAS, Google Scholar
39 Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J: Early virologic response to treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C. Hepatology38,645–652 (2003).Crossref, Medline, CAS, Google Scholar
40 Raptopoulou M, Tsantoulas D, Vafiadi I et al.: The effect of adherence to therapy on sustained response in daily or three times a week interferon α-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. J. Viral Hepat.12,91–95 (2005).Crossref, Medline, CAS, Google Scholar
41 Bacon BR, McHutchison JG: Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am. J. Manag. Care11,S296–S306 (2005).Medline, Google Scholar

Vol. 8, No. 10

Metrics

Downloaded 186 times

History

Published online 2 November 2007

Published in print October 2007

Information

Keywords

Acknowledgement

The authors extend their sincere appreciation to Vita Genomics, Inc. for funding the research and to Pei-Jer Chen of the Hepatitis Research Center, National Taiwan University, You-Chen Chao of the Tri-Service General Hospital, Ming-Lung Yu of the Kaohsiung Medical University Hospital, and Chuan-Mo Lee of the Kaohsiung Chang-Gung Memorial Hospital for research collaboration. The authors also would like to thank Charles Wang for helpful suggestions.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The author states that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download